| Biomarker ID | 910 |
| PMID | 22542564 |
| Year | 2012 |
| Biomarker | PCA3 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upreregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PCa VS No PCa group |
| Type of Biomarker | Diagnostic |
| Cohort | 67 patients with Benign Prostatic Hyperplasia, 36 with High Grade PIN, and 48 with Prostate Cancer were selected for the study. |
| Senstivity | 0.81 [95% CI: 0.68–0.91] |
| Specificity | 0.57 [95% CI: 0.45–0.69] |
| AUC | 0.71 |
| Accuracy | NA |
| Level Of Significance | p< 0.001 |
| Method Used | Progensa PCA3 assay |
| Clinical | No |
| Remarks | PCA3 score is calculated as [(PCA3 mRNA / PSA mRNA) × 1000] |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PCA3 |